Stock Events

Stock Events

Accustem Sciences 

$0.27
15
+$0.01+3.49% Monday 16:08

Statistics

Day High
0.27
Day Low
0.27
52W High
2.21
52W Low
0.26
Volume
-
Avg. Volume
-
Mkt Cap
4.34M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-3.01MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACUT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap160.88B
Gilead Sciences focuses on oncology products that could compete with Accustem's cancer stem cell targeting therapies.
AMGEN
AMGN
Mkt Cap176.21B
Amgen has a broad portfolio in oncology and biotechnology treatments that could overlap with Accustem's therapeutic areas.
Merck
MRK
Mkt Cap275.09B
Merck & Co. is a leader in cancer treatments, including immunotherapy, which could be in direct competition with Accustem's offerings.
Pfizer
PFE
Mkt Cap144.37B
Pfizer has a diverse oncology division, potentially competing with Accustem in the cancer treatment market.
Bristol-Myers Squibb
BMY
Mkt Cap116.4B
Bristol Myers Squibb offers various cancer treatments, including cellular therapies that could compete with Accustem's approach.
Novartis
NVS
Mkt Cap282.55B
Novartis AG has a strong presence in oncology, with treatments that could directly compete with Accustem's products.
Roche
RHHBY
Mkt Cap329.03B
Roche Holding AG is a major player in cancer diagnostics and treatments, potentially competing with Accustem's diagnostic and therapeutic products.
Astrazeneca
AZN
Mkt Cap281.6B
AstraZeneca operates in similar therapeutic areas as Accustem, with a focus on oncology, which could make it a direct competitor.
Lilly(Eli) &
LLY
Mkt Cap896.13B
Eli Lilly and Company has a growing oncology segment that could compete with Accustem's cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.2B
Regeneron Pharmaceuticals focuses on innovative treatments, including for cancer, which could place it in competition with Accustem Sciences.

About

AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
Show more...
CEO
Mr. Gabriele Marco Antonio Cerrone M.B.A.
Employees
2
Country
United States
ISIN
US00444A1016

Listings

OTC Link
US
ACUT

0 Comments

Share your thoughts

FAQ

What is Accustem Sciences stock price today?▼
The current price of ACUT is $0.27 USD — it has increased by +3.49% in the past 24 hours. Watch Accustem Sciences stock price performance more closely on the chart.
What is Accustem Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Accustem Sciences stocks are traded under the ticker ACUT.
Is Accustem Sciences stock price growing?▼
ACUT stock has risen by +0% compared to the previous week, the month change is a -15.62% fall, over the last year Accustem Sciences has showed a -47.03% decrease.
What is Accustem Sciences market cap?▼
Today Accustem Sciences has the market capitalization of 4.34M
What is Accustem Sciences revenue for the last year?▼
Accustem Sciences revenue for the last year amounts to 0 USD.
What is Accustem Sciences net income for the last year?▼
ACUT net income for the last year is -3.01M USD.
How many employees does Accustem Sciences have?▼
As of May 20, 2026, the company has 2 employees.
In which sector is Accustem Sciences located?▼
Accustem Sciences operates in the Health & Wellness sector.
When did Accustem Sciences complete a stock split?▼
Accustem Sciences has not had any recent stock splits.
Where is Accustem Sciences headquartered?▼
Accustem Sciences is headquartered in New York, United States.